EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model

Jason E Cummings, Lisa K Woolhiser, Vincent Guglielmi, Ashely Romano, Samantha Pauly, Matt Zimmerman iD, Firat Kaya, Nicholas D Walter iD, Gregory T Robertson iD, Richard A Slayden iD

Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)

DOI: 10.1128/aac.01953-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Jason E Cummings und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Nitroimidazoles, Oxazoles, Antitubercular Agents, Diarylquinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The bedaquiline, pretomanid, and linezolid (BPaL) regimen has shown significant efficacy in treating patients with multidrug-resistant and extensively drug-resistant tuberculosis. This study assessed whether delamanid, a closely related nitroimidazole, could replace pretomanid in the BPaL regimen by directly comparing the efficacy of bedaquiline, delamanid, and linezolid (BDL) and BPaL regimens in a high-burden preclinical Mycobacterium tuberculosis mouse model. Treatment with pretomanid and delamanid monotherapies and dual therapy with bedaquiline–linezolid was also conducted for comparison. Mice were treated for 2, 4, or 8 weeks, and treatment efficacy was assessed by reductions in lung colony-forming units (CFU), effect size, ribosomal RNA synthesis ratio (RS ratio), and histopathological changes. BPaL showed greater early reduction than BDL, with better CFU reduction kinetics on day 12 (3.96 log 10 CFU reduction for BPaL vs 2.89 log 10 CFU reduction for BDL, P < 0.001) and a lower RS ratio. By day 26, both BPaL and BDL reduced bacterial counts by nearly 6 log 10 CFU, and by day 54 of treatment, lung CFU levels in both groups had fallen below detectable levels. Histopathological analysis revealed slightly improved lung inflammation during early treatment in BPaL-treated mice compared to BDL. Plasma-drug levels were measured, confirming that exposures between regimens over the 24-h dosing interval were comparable and not significantly different. These results suggest that although pretomanid remains the preferred component of the BPaL regimen, delamanid could be a viable alternative if there are clinical reasons to substitute, including drug resistance or if pretomanid is unavailable or poorly tolerated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitroimidazolesOxazolesAntitubercular AgentsDiarylquinolinesLinezolidMycobacterium tuberculosisTuberculosis, PulmonaryAnimalsMiceDisease Models, AnimalLungFemaleMice, Inbred BALB CDrug Therapy, Combination

Stichwörter der Autor:innen

high burdenhigh-burden aerosol BALB/c modeltuberculosis

Substanzen

NitroimidazolespretomanidbedaquilineOPC-67683OxazolesAntitubercular AgentsDiarylquinolinesLinezolid

Autor:innen und Institutionen

  • Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
  • Consortium for Applied Microbial Metrics, Aurora, Colorado, USA.
  • Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Center for Discovery and Innovation, Nutley, New Jersey, USA.
  • Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA.

ORCID-Profile: Matt Zimmerman, Nicholas D Walter, Gregory T Robertson, Richard A Slayden

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Cummings, J. E., Woolhiser, L. K., Guglielmi, V., Romano, A., Pauly, S., Zimmerman, M., Kaya, F., Walter, N. D., Robertson, G. T., & Slayden, R. A. (2026). Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01953-25

Vancouver

Cummings JE, Woolhiser LK, Guglielmi V, Romano A, Pauly S, Zimmerman M, et al. Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01953-25

BibTeX
@article{Cummings2026,
  author = {Cummings, Jason E and Woolhiser, Lisa K and Guglielmi, Vincent and Romano, Ashely and Pauly, Samantha and Zimmerman, Matt and Kaya, Firat and Walter, Nicholas D and Robertson, Gregory T and Slayden, Richard A},
  title = {Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {6},
  doi = {10.1128/aac.01953-25}
}
Kostenlos starten →